Sugi Predict

Sugi Predict / Compounds / SCHEMBL2727920

SCHEMBL2727920

SCHEMBL2727920

O=C(O)CNc1cc(Cl)cc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FABP4 P15090 2/20 0.49
▸ MEN1 O00255 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ THRA P10827 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ TPMT P51580 1/20 0.43
▸ ACP1 P24666 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ GRM4 Q14833 2/20 0.40
▸ CDC25A P30304 1/20 0.40
▸ P2RY1 P47900 1/20 0.39
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17546644 0.87 THRA (0.40) FABP4MEN1MAPTKMT2ANPSR1
SCHEMBL2728214 0.87 GRM4 (0.46) FABP4MEN1KMT2ARAB9ATHRA
SCHEMBL2728422 0.82 P2RX1 (0.57) MEN1KMT2A
SCHEMBL18466195 0.81 L3MBTL1 (0.43) FABP4MEN1MAPTKMT2ANPSR1
SCHEMBL30421886 0.80 MEN1 (0.56) MEN1MAPTKMT2ARAB9A
SCHEMBL157003 0.80 MEN1 (0.56) MEN1MAPTKMT2ARAB9A
Hydrochloric Acid SCHEMBL28590040 0.80 MEN1 (0.56) MEN1MAPTKMT2ARAB9A
Hydrochloric Acid SCHEMBL30605752 0.80 MEN1 (0.56) MEN1MAPTKMT2ARAB9A
SCHEMBL4586266 0.79 THRA (0.46) MAPTTHRATHRBCDC25APOLB
SCHEMBL3465248 0.79 THRA (0.49) MAPTTHRATHRBCDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220098154-A1 ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-03-31 — — US disclosed
EP-3917627-A1 ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2021-12-08 — — EP disclosed
CN-113316394-A Process for preparing high intensity sweeteners 弗门尼舍公司 2021-08-27 — — CN disclosed
CN-113286523-A Process for preparing high intensity sweeteners 弗门尼舍公司 2021-08-20 — — CN disclosed
EP-3836919-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF Recreo Pharmaceuticals Inc. (US) 2021-06-23 — — EP disclosed
US-20210163479-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF RECREO PHARMACEUTICALS LLC (US) 2021-06-03 — — US disclosed
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase UNIVERSITY OF WASHINGTON (US) 2021-02-09 — — US disclosed
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase UNIVERSITY OF WASHINGTON (US) 2021-02-09 — — US disclosed
WO-2020160134-A1 ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-08-06 — — WO disclosed
WO-2020160134-A1 ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-08-06 — — WO disclosed
US-20170027956-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. 2017-02-02 — — US disclosed
US-20170027956-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. 2017-02-02 — — US disclosed
US-20170027956-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. 2017-02-02 — — US disclosed
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 — — US disclosed
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 — — US disclosed
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 — — US disclosed
US-20130345192-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2013-12-26 — — US disclosed
EP-2632898-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS Biogen Idec MA Inc. (US) 2013-09-04 — — EP disclosed
WO-2012058645-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2012-05-03 — — WO disclosed
WO-2012058645-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2012-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098154-A1 ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS POLQ, POLH, POLB FABP4 3972/4885MEN1 4651/4885MAPT 2755/4885
US-20210163479-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA1, FOXM1 FABP4 4838/4885MEN1 1942/4885MAPT 4739/4885
US-20170027956-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS TEC, ABL1, LCK FABP4 4783/4885MEN1 2539/4885MAPT 1648/4885
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase AARS1, MTR, GARS1 FABP4 3487/4885MEN1 2418/4885MAPT 3016/4885
US-20130345192-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS TEC, ABL1, LCK FABP4 4783/4885MEN1 2539/4885MAPT 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback